Results 111 to 120 of about 616,871 (170)
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.
Miao H +28 more
europepmc +1 more source
Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study. [PDF]
Batayneh O +10 more
europepmc +1 more source
The tumor suppressor menin is a key scaffold mediator for homologous recombination repair. [PDF]
Lian A +8 more
europepmc +1 more source
Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance. [PDF]
Rojas A +3 more
europepmc +1 more source
Identification and Management of Differentiation Syndrome in Emergency Settings: A Narrative Review. [PDF]
Chang GA +4 more
europepmc +1 more source
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions. [PDF]
Ko KH, Gelfer R, Wheat JC, Cai SF.
europepmc +1 more source
The role of menin inhibitors in acute myeloid leukemia
Purpose of review Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.
Isidori A., Marconi G.
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy
Blood, 2023The chromatin adaptor protein Menin ( MEN1) is necessary for sustained proliferation in acute leukemias driven either by Lysine Methyltransferase 2A (MLL1/ KMT2A) gene rearrangements. Small molecule Menin inhibitors (MIs) disrupt the MENIN-KMT2A protein interaction by competing with KMT2A for a binding pocket in Menin.
Jevon Cutler +12 more
openaire +1 more source

